Proactive pediatric inflammatory bowel disease testing


Live via Zoom: 20-minute recorded presentation followed by 10-minute Q&A discussion

Mayo Clinic Laboratories’ approach to pediatric gastroenterology testing is underscored by our commitment to meeting the needs of every patient – from the tallest to the smallest. Our menu of integrated pediatric and adult testing enables coordinated evaluations of family members who display similar gastrointestinal presentation. Our monogenetic inflammatory bowel disease (IBD) test (IBDGP) can identify genetic variations associated with inherited disorders, and our thiopurine genotyping test (TPNUQ) can detect variations in genes with known associations to irregular metabolization of IBD medications. Both evaluations offer insights that can improve treatment outcomes.

Increase your understanding of proactive testing

You are invited to join molecular genetic pathologist Ann Moyer, M.D., Ph.D., on Monday, June 27, at 11 a.m. CT for a presentation and Q&A discussion on how our genetic panels can improve outcomes in pediatric patients suspected of IBD. Hosted by Delta Lane, senior product manager, the webinar will highlight how Mayo Clinic Laboratories testing can proactively identify IBD-associated biomarkers prior to therapy initiation in young patients who present with IBD symptoms.

Learning objectives

  1. Discuss opportunities in testing prior to, during, and post thiopurine therapy in young patients.
  2. Assess how enzyme and genotype testing can be used together to assess patient risk prior to thiopurine therapy initiation. 
  3. Discuss how isolating the genetic cause of the illness enables clinicians to clarify and confirm diagnosis and guide treatment choices. 

Resources

For more information on our pediatric tests and services, click here.

Robin Huiras-Carlson (@robinh)

Robin Huiras-Carlson

Robin Huiras-Carlson is a senior marketing specialist at Mayo Clinic Laboratories and a Mayo Clinic employee since 2015. Her writing focuses on specialty testing, innovation, and patient-focused initiatives.